We propose that cryptic HDGFL2 levels may peak presymptomatically in some individuals and decrease as disease progresses, and thus measurement of CSF cryptic HDGFL2 may provide the ability to predict phenoconversion in familial ALS–FTD, particularly when evaluated in combination with CSF NF levels. Here, HDGFL2 is linked to frontotemporal dementia.